JELLY_1170x120_9-8-20

oncology

Merck to buy ArQule, advancing leadership in oncology

Merck to buy ArQule, advancing leadership in oncology

KENILWORTH, N.J. — Merck and ArQule announced Monday that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development

Pfizer to buy Medivation for $14 billion

Pfizer to buy Medivation for $14 billion

NEW YORK  — Boosting its oncology portfolio, Pfizer Inc. plans to acquire biopharmaceutical company Medivation for $14 billion in cash. Under the deal announced Monday, Pfizer is paying $81.50 a share in cash for San Francisco-based Medivation, whose products include XTANDI (enzalutamide), an androgen receptor inhibitor that the companies said is the nation’s leading novel